Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Phase 2 Not yet recruiting

74 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06441565 2025-07-30

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Phase 2/3 Recruiting

84 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

52 enrolled 23 charts

BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05771181 2025-06-12

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06985316 2025-05-22

An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

Phase NA Not yet recruiting

34 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06980532 2025-05-20

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

Phase 1/2 Recruiting

42 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04322539 2025-04-04

FRESCO-2

Phase 3 Completed

691 enrolled 26 charts 1 FDA

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06714903 2024-12-04

Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer

Recruiting

50 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06551207 2024-08-13

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Phase NA Recruiting

80 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Phase 2 Recruiting

68 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05690035 2024-07-09

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06470178 2024-06-24

A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents

Not yet recruiting

70 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06148402 2024-05-13

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05661357 2024-04-17

HCCSC-C03

Phase 4 Unknown

51 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06347198 2024-04-04

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Phase EARLY_PHASE1 Unknown

30 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06234007 2024-03-18

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

Phase 2 Recruiting

45 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05435313 2024-01-17

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Phase 2 Unknown

39 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06202417 2024-01-11

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Completed

520 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05522738 2024-01-08

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Phase 1/2 Unknown

46 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06195670 2024-01-08

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Phase 1/2 Not yet recruiting

220 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06168786 2023-12-21

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06118762 2023-11-07

Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

Phase 4 Recruiting

30 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06031376 2023-09-11

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Completed

106 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06018714 2023-08-31

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

Phase 2 Recruiting

64 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05025631 2023-04-28

DOFEMCRC

Phase 2 Completed

29 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05747716 2023-02-28

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Phase 2 Not yet recruiting

44 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05634590 2022-12-02

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Phase 2 Unknown

68 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05368805 2022-10-06

Fruquintinib DDI Study With P-gp and BCRP Substrates

Phase 1 Completed

32 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

COFRUQ

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

IGNITE-CRC

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

FRUITFUL

FRUITION

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

FRESCO-2

Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

HCCSC-C03

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

DOFEMCRC

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Fruquintinib DDI Study With P-gp and BCRP Substrates